Actively Recruiting
International Leukemia Target Board
Led by Princess Maxima Center for Pediatric Oncology · Updated on 2026-01-09
600
Participants Needed
7
Research Sites
491 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician. The iLTB will discuss molecular (genetic lesions), immunophenotypic/surface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation/CAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregated level. As such the iLTB is non-interventional as it mainly provides advice and registers data on patients discussed in the iLTB.
CONDITIONS
Official Title
International Leukemia Target Board
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The patient has been diagnosed with a relapsed or refractory hematological malignancy
- The patient is less than 18 years old at first diagnosis and less than 25 years old at inclusion with relapsed/refractory disease
- The patient is treated in a pediatric or adolescent/young adult setting or study protocol with no current standard treatment
- The patient has a life expectancy of at least 6 weeks
- The patient has undergone molecular profiling of their tumor and results are available
- The patient has undergone flow cytometry in a certified lab and results are available
- Written informed consent from patient and/or parent(s)/guardian(s) to discuss the patient in the iLTB has been obtained
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
UH Gent
Ghent, Belgium
Actively Recruiting
2
Righospitalet
Copenhagen, Denmark
Actively Recruiting
3
Semmelweis
Budapest, Hungary
Actively Recruiting
4
Princess Máxima Center for Pediatric Oncology
Utrecht, Utrecht, Netherlands, 3584CS
Actively Recruiting
5
Vall d'Hebron
Barcelona, Spain
Actively Recruiting
6
Queen Silvia
Gothenburg, Sweden
Actively Recruiting
7
Newcastle Hospital
Newcastle, United Kingdom
Actively Recruiting
Research Team
U
Uri Ilan, MD
CONTACT
A
Anne Elsinghorst
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here